STOCK TITAN

[144] BeOne Medicines Ltd. American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) Form 144 notice: The filer notified a proposed sale of 5,000 ADS through Morgan Stanley Smith Barney at an aggregate market value of $1,732,250.00, with an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired on 05/17/2022 by previously exercised stock options and paid in cash. The filing also discloses recent sales by the related parties: 7,675 ADS were sold during the past three months in multiple transactions generating gross proceeds of $2,210,354.28. The filer affirms no undisclosed material adverse information and, where applicable, reliance on a trading plan or instructions is noted in the form.

Avviso Form 144 di BeOne Medicines Ltd. (ONC): Il dichiarante ha comunicato la proposta di vendita di 5.000 ADS tramite Morgan Stanley Smith Barney per un valore complessivo di mercato di $1.732.250,00, con data approssimativa di vendita il 09/09/2025 su NASDAQ. I titoli sono stati acquisiti il 17/05/2022 mediante opzioni su azioni esercitate in precedenza e pagati in contanti. La dichiarazione riporta anche vendite recenti da parte di soggetti correlati: 7.675 ADS vendute negli ultimi tre mesi in più transazioni, per un ricavo lordo di $2.210.354,28. Il dichiarante conferma l'assenza di informazioni materiali non divulgate e, se applicabile, indica il ricorso a un piano di negoziazione o a istruzioni specifiche nel modulo.

Aviso Form 144 de BeOne Medicines Ltd. (ONC): El declarante notificó una propuesta de venta de 5.000 ADS a través de Morgan Stanley Smith Barney por un valor de mercado agregado de $1.732.250,00, con fecha aproximada de venta el 09/09/2025 en NASDAQ. Los títulos fueron adquiridos el 17/05/2022 mediante opciones sobre acciones previamente ejercidas y pagados en efectivo. La presentación también revela ventas recientes de partes relacionadas: 7.675 ADS vendidas en los últimos tres meses en múltiples transacciones, generando ingresos brutos de $2.210.354,28. El declarante afirma que no existen informaciones materiales no divulgadas y, cuando procede, indica la dependencia de un plan de negociación o instrucciones en el formulario.

BeOne Medicines Ltd. (ONC) Form 144 통지: 제출인은 Morgan Stanley Smith Barney를 통해 총 시장 가치 $1,732,250.00 규모의 5,000 ADS 매각 예정 사실을 통지했으며, 대략적인 매각일은 2025-09-09로 NASDAQ에서 진행될 예정입니다. 해당 증권은 2022-05-17에 이전에 행사한 주식옵션으로 취득했고 현금으로 지급되었습니다. 제출서에는 관련 당사자들의 최근 매각 내역도 공시되어 있는데, 과거 3개월 동안 여러 거래로 7,675 ADS가 매각되어 총 수익 $2,210,354.28을 발생시켰습니다. 제출인은 공개되지 않은 중대한 불리한 정보가 없음을 확인하며, 해당되는 경우 거래계획 또는 지시에 따른 것임을 서식에 명시하고 있습니다.

Avis Formulaire 144 de BeOne Medicines Ltd. (ONC) : Le déclarant a notifié la vente projetée de 5 000 ADS via Morgan Stanley Smith Barney pour une valeur de marché globale de 1 732 250,00 $, avec une date approximative de vente au 09/09/2025 sur le NASDAQ. Les titres ont été acquis le 17/05/2022 par l'exercice antérieur d'options sur actions et payés en espèces. Le dépôt révèle également des ventes récentes par des parties liées : 7 675 ADS vendues au cours des trois derniers mois lors de plusieurs transactions, générant des produits bruts de 2 210 354,28 $. Le déclarant affirme l'absence d'informations défavorables substantielles non divulguées et, le cas échéant, indique le recours à un plan de négociation ou à des instructions dans le formulaire.

Form 144-Mitteilung von BeOne Medicines Ltd. (ONC): Der Einreicher hat einen geplanten Verkauf von 5.000 ADS über Morgan Stanley Smith Barney bekanntgegeben, mit einem Gesamtmarktwert von $1.732.250,00 und einem voraussichtlichen Verkaufsdatum am 09.09.2025 an der NASDAQ. Die Wertpapiere wurden am 17.05.2022 durch zuvor ausgeübte Aktienoptionen erworben und in Bargeld bezahlt. Die Meldung enthält außerdem Angaben zu jüngsten Verkäufen verbundener Personen: In den letzten drei Monaten wurden in mehreren Transaktionen 7.675 ADS verkauft und Bruttoerlöse von $2.210.354,28 erzielt. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen und weist gegebenenfalls auf die Nutzung eines Handelsplans oder von Anweisungen im Formular hin.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insider-related sales disclosed: planned 5,000 ADS sale and 7,675 ADS sold recently, totaling over $2.2M proceeds.

The filing clearly lists a proposed sale of 5,000 ADS (aggregate market value $1.73M) to be executed via Morgan Stanley Smith Barney on 09/09/2025 and documents acquisition by exercised options paid in cash on 05/17/2022. Recent dispositions by related parties and the named individual (Lai Wang and Wang Holdings LLC) total 7,675 ADS with gross proceeds of $2,210,354.28. For investors, these are transparent disclosures of insider liquidity events; the filing does not provide reasons for selling or any forward-looking plans beyond the stated dates.

TL;DR: Governance disclosure is routine and complete for a Form 144; signatures and representations are included.

The form includes the required representation that the seller is unaware of undisclosed material adverse information and references potential reliance on Rule 10b5-1 plans. Acquisition details (date and nature) and payment form are provided, meeting the form's disclosure standards. The record of multiple recent sales by related parties should be evaluated in the context of corporate governance and insider trading policies, but the filing itself contains the necessary factual information without commentary.

Avviso Form 144 di BeOne Medicines Ltd. (ONC): Il dichiarante ha comunicato la proposta di vendita di 5.000 ADS tramite Morgan Stanley Smith Barney per un valore complessivo di mercato di $1.732.250,00, con data approssimativa di vendita il 09/09/2025 su NASDAQ. I titoli sono stati acquisiti il 17/05/2022 mediante opzioni su azioni esercitate in precedenza e pagati in contanti. La dichiarazione riporta anche vendite recenti da parte di soggetti correlati: 7.675 ADS vendute negli ultimi tre mesi in più transazioni, per un ricavo lordo di $2.210.354,28. Il dichiarante conferma l'assenza di informazioni materiali non divulgate e, se applicabile, indica il ricorso a un piano di negoziazione o a istruzioni specifiche nel modulo.

Aviso Form 144 de BeOne Medicines Ltd. (ONC): El declarante notificó una propuesta de venta de 5.000 ADS a través de Morgan Stanley Smith Barney por un valor de mercado agregado de $1.732.250,00, con fecha aproximada de venta el 09/09/2025 en NASDAQ. Los títulos fueron adquiridos el 17/05/2022 mediante opciones sobre acciones previamente ejercidas y pagados en efectivo. La presentación también revela ventas recientes de partes relacionadas: 7.675 ADS vendidas en los últimos tres meses en múltiples transacciones, generando ingresos brutos de $2.210.354,28. El declarante afirma que no existen informaciones materiales no divulgadas y, cuando procede, indica la dependencia de un plan de negociación o instrucciones en el formulario.

BeOne Medicines Ltd. (ONC) Form 144 통지: 제출인은 Morgan Stanley Smith Barney를 통해 총 시장 가치 $1,732,250.00 규모의 5,000 ADS 매각 예정 사실을 통지했으며, 대략적인 매각일은 2025-09-09로 NASDAQ에서 진행될 예정입니다. 해당 증권은 2022-05-17에 이전에 행사한 주식옵션으로 취득했고 현금으로 지급되었습니다. 제출서에는 관련 당사자들의 최근 매각 내역도 공시되어 있는데, 과거 3개월 동안 여러 거래로 7,675 ADS가 매각되어 총 수익 $2,210,354.28을 발생시켰습니다. 제출인은 공개되지 않은 중대한 불리한 정보가 없음을 확인하며, 해당되는 경우 거래계획 또는 지시에 따른 것임을 서식에 명시하고 있습니다.

Avis Formulaire 144 de BeOne Medicines Ltd. (ONC) : Le déclarant a notifié la vente projetée de 5 000 ADS via Morgan Stanley Smith Barney pour une valeur de marché globale de 1 732 250,00 $, avec une date approximative de vente au 09/09/2025 sur le NASDAQ. Les titres ont été acquis le 17/05/2022 par l'exercice antérieur d'options sur actions et payés en espèces. Le dépôt révèle également des ventes récentes par des parties liées : 7 675 ADS vendues au cours des trois derniers mois lors de plusieurs transactions, générant des produits bruts de 2 210 354,28 $. Le déclarant affirme l'absence d'informations défavorables substantielles non divulguées et, le cas échéant, indique le recours à un plan de négociation ou à des instructions dans le formulaire.

Form 144-Mitteilung von BeOne Medicines Ltd. (ONC): Der Einreicher hat einen geplanten Verkauf von 5.000 ADS über Morgan Stanley Smith Barney bekanntgegeben, mit einem Gesamtmarktwert von $1.732.250,00 und einem voraussichtlichen Verkaufsdatum am 09.09.2025 an der NASDAQ. Die Wertpapiere wurden am 17.05.2022 durch zuvor ausgeübte Aktienoptionen erworben und in Bargeld bezahlt. Die Meldung enthält außerdem Angaben zu jüngsten Verkäufen verbundener Personen: In den letzten drei Monaten wurden in mehreren Transaktionen 7.675 ADS verkauft und Bruttoerlöse von $2.210.354,28 erzielt. Der Einreicher bestätigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen und weist gegebenenfalls auf die Nutzung eines Handelsplans oder von Anweisungen im Formular hin.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for ONC disclose about the proposed sale?

The notice reports a proposed sale of 5,000 ADS through Morgan Stanley Smith Barney with an aggregate market value of $1,732,250.00 and an approximate sale date of 09/09/2025.

How and when were the ADS being sold acquired according to the filing?

The 5,000 ADS were acquired on 05/17/2022 through previously exercised stock options and payment was made in cash.

What insider or related-party sales occurred in the last three months per the filing?

The filing shows five transactions totaling 7,675 ADS sold by Wang Holdings LLC and Lai Wang on dates between 06/16/2025 and 07/29/2025, with combined gross proceeds of $2,210,354.28.

Does the filer state they have undisclosed material information?

By signing the form, the person represents they do not know of any material adverse information

Is there an indication the sales are part of a Rule 10b5-1 plan?

The filing references Rule 10b5-1 sales and includes a field for the date of plan adoption or instruction; specific plan adoption dates are included where applicable in the form.

Which exchange is listed for the proposed sale of ADS?

The proposed sale lists NASDAQ as the securities exchange for the transaction.
Beigene Ltd

NASDAQ:ONC

ONC Rankings

ONC Latest News

ONC Latest SEC Filings

ONC Stock Data

38.12B
91.06M
17.24%
32.34%
1.64%
Biotechnology
Pharmaceutical Preparations
Link
Switzerland
BASEL